Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
classes:
Anti-CGRP ligand monoclonal antibody (2) ·
[[:Category:Antihistamines|Antihistamine]] (1) ·
[[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (1) ·
[[:Category:Basal_insulins|Basal insulin]] (2) ·
[[:Category:Expectorants|Expectorant]] (1) ·
[[:Category:H1_receptor_antagonists|Histamine H1 receptor antagonist (second-generation)]] (1) ·
[[:Category:Insulins|Insulin]] (2) ·
[[:Category:Insulin_secretagogues|Insulin secretagogue]] (1) ·
[[:Category:Long-acting_insulins|Long-acting insulin analog]] (2) ·
[[:Category:Mucolytics|Mucolytic]] (1) ·
[[:Category:Sulfonylureas|Sulfonylurea (third-generation)]] (1)
mechanism:
None (2) ·
Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) ·
Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) ·
'"`UNIQ--vote-00000237-QINU`"' Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio; provides basal hepatic glucose suppression and peripheral glucose uptake without prandial peaks'"`UNIQ--ref-00000238-QINU`"'. (1) ·
'"`UNIQ--vote-00000CC9-QINU`"' Mostly excreted unchanged in feces and urine; P-glycoprotein substrate (the basis of the fruit-juice interaction). (1) ·
'"`UNIQ--vote-0000104D-QINU`"' Adequate hydration is at least as important as the drug in producing the expectorant effect clinically. Used in combination with dextromethorphan, decongestants, or antihistamines in many proprietary OTC cold preparations. (1)
uses:
Preventive treatment of migraine in adults (episodic and chronic) (1) ·
Preventive treatment of migraine in adults; episodic cluster headache (1) ·
'"`UNIQ--vote-00000239-QINU`"', '"`UNIQ--vote-0000023A-QINU`"' (1) ·
'"`UNIQ--vote-00000491-QINU`"' (1) ·
'"`UNIQ--vote-00000CCA-QINU`"', '"`UNIQ--vote-00000CCB-QINU`"' (1) ·
'"`UNIQ--vote-0000104E-QINU`"', '"`UNIQ--vote-0000104F-QINU`"' (1) ·
'"`UNIQ--vote-00001372-QINU`"', '"`UNIQ--vote-00001373-QINU`"' (1)
starting dose:
1-2 mg PO once daily with breakfast; titrate by glycemic response (1) ·
200-400 mg PO q4h (IR); 600-1200 mg PO q12h (Mucinex 12-Hour ER) (1) ·
225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) ·
60 mg PO BID or 180 mg PO once daily (1) ·
Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1) ·
~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose (1) ·
~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose. Frequently dosed BID at moderate-to-high doses (1)
preparations:
1 mg, 2 mg, 4 mg tablets (1) ·
100 U/mL (Lantus, Basaglar, Semglee) vials and pens; 300 U/mL (Toujeo) pens (1) ·
100 U/mL FlexTouch pen, vial (1) ·
100, 200, 400 mg IR tablets; 600 mg, 1200 mg Mucinex ER tablets; many liquid formulations and combination products with dextromethorphan, pseudoephedrine, antihistamines (1) ·
120 mg/mL prefilled syringe or autoinjector (1) ·
225 mg/1.5 mL prefilled syringe or autoinjector (1) ·
30, 60, 180 mg tablets; 30 mg ODT; 6 mg/mL oral suspension; all OTC (1)
fda max:
onset: (Click arrow to add another value)
duration:
halflife:
~1 hour'"`UNIQ--ref-00001050-QINU`"' (1) ·
~12 hours apparent (functional duration ~24 hours due to depot release kinetics)'"`UNIQ--ref-0000023B-QINU`"' (1) ·
~14 hours'"`UNIQ--ref-00000CCC-QINU`"' (1) ·
~27 days (1) ·
~31 days (1) ·
~5-9 hours (parent and active metabolites combined)'"`UNIQ--ref-00000492-QINU`"' (1) ·
~7 hours apparent'"`UNIQ--ref-00001374-QINU`"' (1)
bioavailability:
High (oral)'"`UNIQ--ref-00001051-QINU`"' (1) ·
Not formally established (1) ·
Not formally established (high SC) (1) ·
~100% (oral; not significantly affected by food)'"`UNIQ--ref-00000493-QINU`"' (1) ·
~100% from subcutaneous depot (by definition of the route) (1) ·
~33% (oral; fruit juices including grapefruit, orange, and apple reduce absorption substantially via OATP1A2 inhibition — distinctive interaction not seen with most other H1s)'"`UNIQ--ref-00000CCD-QINU`"' (1) ·
~60% from subcutaneous depot (reduced by reversible albumin binding via the myristic acid side chain that also extends duration)'"`UNIQ--ref-00001375-QINU`"' (1)
pregnancy:
Avoid; switch to insulin. Neonatal hypoglycemia reported.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered acceptable.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; loratadine and cetirizine have more pregnancy data and are typically preferred.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Insulin is the preferred glucose-lowering therapy in pregnancy; glargine has reassuring observational data, though NPH and detemir remain the traditional choices.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; avoid (2) ·
One of the better-studied basal insulin analogs in pregnancy; reassuring data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 7 results in range #1 to #7.